Selecta Biosciences is a biopharmaceutical company developing first-in-class synthetic nanoparticle vaccines using its proprietary targeted Synthetic Vaccine Particle (tSVP™) technology. The tSVP platform enables full integration of the key vaccine components – antigens and adjuvants – for highly-effective targeting to immune cells to produce the optimal immune response. tSVP vaccines mimic the structure of natural pathogens with regards to size, shape and the sequence of immunological information that it delivers to immune cells, thus harnessing the body’s defense system to elicit a robust humoral and/or cellular immune response.

The unique attributes of full integration, targeting and natural structure conferred by the tSVP platform create synthetic nanoparticle vaccines that are engineered for unprecedented safety and efficacy.  This novel approach enables expanded opportunities for vaccines using Selecta’s tSVP platform, and the company is pursuing opportunities across a range of therapeutic areas, including infectious, metabolic, CNS, and inflammatory diseases.

Selecta was founded based on breakthrough discoveries in immunobiology and nanotechnology by three scientific pioneers. Selecta’s broad and powerful product platform brings together the advanced particle technology of Professors Robert Langer (MIT) and Omid Farokhzad (Harvard Medical School), two leaders in the fields of drug delivery and targeted nanotechnology, combined with the insights into the workings of the immune system made by Professor Ulrich von Andrian (Harvard Medical School), a leader in the field of immunology.

Selecta is backed by leading venture investors including, Polaris Venture Partners, Flagship Ventures, NanoDimension, OrbiMed Advisors and Leukon Investments. Selecta's intellectual property portfolio consists of a broad patent estate of issued and pending patent applications covering vaccine nanoparticles, targeted delivery, controlled-release polymer systems, novel adjuvants, novel antigens, and nanoparticle formulation and processing for therapeutic and prophylactic vaccines, and immunomodulatory applications.